Clinical outcomes and safety of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) in patients aged < 75 and ≥ 75 years: ARCHES post hoc analysis

Autor:	Russell Zelig Szmulewitz, Jeffrey Holzbeierlein, Arun Azad, Taro Iguchi, Arnauld Villers, Antonio Alcaraz, Boris Alekseev, Neal D. Shore, Brad Rosbrook, Fabian Zohren, Jie Ma, Gabriel P. Haas, Francisco Gomez-Veiga, Arnulf Stenzl, Andrew J. Armstrong
Rok vydání:	2022
Předmět:	Cancer Research Oncology
Zdroj:	Journal of Clinical Oncology. 40:5069-5069
ISSN:	1527-7755 0732-183X
Popis:	5069 Background: Patients with metastatic prostate cancer aged ≥75 years have a poorer prognosis compared with younger patients. In ARCHES (NCT02677896), ENZA + ADT improved radiographic progression-free survival (rPFS), overall survival (OS), and other key secondary endpoints vs. placebo (PBO) + ADT in patients with mHSPC. Final OS results confirmed a long-term survival benefit with ENZA + ADT. This post hoc analysis of ARCHES data investigated OS and other clinical outcomes in patients aged
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::7c156687f95b6232a7e5c81fa1e1b5ca https://doi.org/10.1200/jco.2022.40.16_suppl.5069 Zobrazit plný text záznamu